Mindstate Design Labs
Clinical-stage AI neuroengineering platform
About
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.
Founders
- Tom Ray
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Mindstate Design Labs.
See family office activity